



Figure 1. Cumulative release of MB from a depot forming a reversed hexagonal $H_{II}$ phase.





*Figure 2. Decrease in viscosity of the depot precursor on addition of solvents. PC/GDO (6/4) is a precursor to a reversed hexagonal $H_{II}$ phase and PC/GDO (3/7) is a precursor to a reversed cubic $I_2$ phase.*





*Figure 3. Plasma concentrations in the rat model after subcutaneous administration of formulations E to I. A depot based on sesame oil was used as reference.*





Figure 4. Plasma concentrations in the rat model after subcutaneous administration of formulations F and G.





Figure 5: Octreotide plasma levels in the rat model following administration of octreotide formulation precursor (0.5% by weight octreotide).





Figure 6: Octreotide plasma levels in the rat model following administration of octreotide formulation P, see Example 45.





Figure 7: Release of Chlorhexidine from formulation A, see Example 47.